Microparticles
The present invention provides microparticles comprising a sulphur-containing compound, such as cysteamine, or a pharmaceutically acceptable salt, hydrate or ester thereof. Also provided is a composition comprising the microparticles and a stabilizing agent.
1. Microparticles comprising: cysteamine or cystamine or a pharmaceutically acceptable salt, hydrate or ester thereof; and a stabilizing agent,
wherein the stabilizing agent is selected from the group consisting of sugar alcohols and trehalose, wherein the microparticles have a particle size of about 2 to 8 microns and wherein the microparticles comprise between 75 and 95% w/w stabilizing agent.
2. The microparticles as claimed in claim 1 wherein the microparticles have a particle size of 2 to 4 microns.
3. The microparticles as claimed in claim 1 which comprise between about 5 and 10% w/w cysteamine or cystamine.
4. The microparticles as claimed in claim 1 which comprise up to 85% w/w stabilizing agent.
5. The microparticles as claimed in claim 1 further comprising leucine.
6. The microparticles as claimed in claim 5 which comprise between 1 and 10% w/w leucine.
7. The microparticles as claimed in claim 1 which are in a dry powder.
8. A therapeutic composition comprising the microparticles as claimed in claim 1 , and at least one additional pharmaceutical agent.
9. The therapeutic composition as claimed in claim 8 wherein the at least one additional pharmaceutical agent is an antibacterial agent.
10. The therapeutic composition as claimed in claim 8 wherein the at least one additional pharmaceutical agent is selected from the group consisting of antibiotics, mucolytic agents, vasodilators, antihypertensive agents, cardiovascular drugs and calcium channel blockers.
11. The therapeutic composition as claimed in claim 10 , wherein the vasodilator is a bronchodilator.
12. The microparticles as claimed in claim 1 which comprise up to 20% or 25% w/w cysteamine or cystamine.
13. The microparticles as claimed in claim 1 , wherein the stabilizing agent is mannitol.
14. An inhalation device comprising the microparticles as claimed in claim 1 .
15. Microparticles comprising 20% w/w cysteamine or cystamine, 75% w/w mannitol, and 5% w/w leucine.
16. A method of treating lung disease comprising administering the microparticles as claimed in claim 1 to a subject suffering, or having previously suffered, from lung disease.
17. The method of claim 16 wherein the lung disease is a respiratory disease.
18. The therapeutic composition method as claimed in claim 17 , wherein the respiratory disease is selected from the group consisting of cystic fibrosis, chronic obstructive pulmonary disease, chronic bronchitis, bronchiectasis, emphysema, chronic obstructive airways disease, chronic cough, common cold, influenza, hantavirus, pneumonia, and pleurisy.